How many insider trades does FilingIQ track for PTHS?

FilingIQ tracks 41 Form 4 insider transactions for PTHS (Pelthos Therapeutics Inc.), covering filings from Jun 14, 2024 onwards. 8 of those were filed in the last 90 days.

Are PTHS insiders net buyers or net sellers?

Across the full Form 4 history for PTHS, 0 transactions (0%) were open-market purchases and 12 (29%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does PTHS insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is PTHS in?

Pelthos Therapeutics Inc. (PTHS) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $74.12M.

PTHS insider trading

NYSE American Healthcare

Pelthos Therapeutics Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

0% / 29%

Market cap

$74.12M

About Pelthos Therapeutics Inc.

Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indicated for topical treatment of head lice infestation in patients 6 months of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina.

Company website: pelthos.com

PTHS insider activity at a glance

FilingIQ has scored 41 insider transactions for PTHS since Jun 14, 2024. The most recent filing in our index is dated Apr 2, 2026.

Across the full history, 0 open-market purchases and 12 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on PTHS insider trades is 50.3/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live PTHS trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for PTHS?: FilingIQ tracks 41 Form 4 insider transactions for PTHS (Pelthos Therapeutics Inc.), covering filings from Jun 14, 2024 onwards. 8 of those were filed in the last 90 days.
Are PTHS insiders net buyers or net sellers?: Across the full Form 4 history for PTHS, 0 transactions (0%) were open-market purchases and 12 (29%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does PTHS insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is PTHS in?: Pelthos Therapeutics Inc. (PTHS) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $74.12M.

Methodology & sources

Every PTHS insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.